Two Miltenyi Biotec employees in lab attire walking down a lab hallway discussing paperwork, graphic bubbles with scientific spotlight written are shown  on right side of the picture

Pause. Take a step back. Learn about people.

Miltenyi Biotec is a community of colleagues fascinated by science and dedicated to empowering cell research. That is our drive. But what makes many of us go the extra mile are the personal contacts we make with researchers around the world. While their work undoubtedly motivates us, their stories as human beings make us smile, reflect, admire, and at times, laugh out loud. Some of them are accomplished athletes. Others lead very different lives outside of the lab. And others yet pursue unexpected hobbies and interests. Each story is unique. Each contact is an opportunity to pause, take a step back, and learn something about people.

The interviews of our Scientific Spotlight are a glimpse into the lives of scientists like you. We hope you enjoy each conversation and find inspiration from their thoughts and experiences exploring the frontiers of the biological sciences.

Interviewees of the Miltenyi Biotec Scientific Spotlight receive no financial or other compensation for their participation.

Dr. Maria Ormhøj

Just do it: building a life, a lab, and a community from the ground up

Interview with Dr. Maria Ormhøj, Assistant Professor in Experimental & Translational Immunology, Department of Health Technology at the Technical University of Denmark (DK)

When you think about Denmark, you might think about Vikings, Lego, the Little Mermaid, and sleek furniture. If Dr. Maria Ormhøj has anything to say about it, you’ll soon add engineered cell therapies to the list. Maria is an Assistant Professor in the Department of Health Technology at the Technical University of Denmark (DTU), and she is eager to make the fledging Danish cell therapy community into a global powerhouse. “It’s a really good thing that we are such a small country because we work well together. I think that can bring us to a lot of important clinical discoveries because we can effectively bridge basic science to clinical practice. That is what I really want to do in Denmark: to bring all of that together and build a strong community within the field.” Maria is a mover and shaker among cell therapy researchers. She organizes conferences for networking. She supervises projects to reimagine how cell therapies work. She built the facilities to translate those reimagined concepts into workable therapies. Becoming that impetus took the occasional leap of faith and the tenacity to see it through, but as one mentor described her, Maria is “as persistent as a T cell.”

Noah Allen researches the impact of microgravity, radiation exposure, and aging on liver health.

In a quest to understand the immune system, Noah Allen took his research to the sky

Interview with Noah Allen, Research Assistant and PhD candidate, Rensselaer Polytechnic Institute (US) and winner of the Immunology Innovator Award

Diagnosed with a fused bicuspid aortic valve as a teenager, Noah Allen understood at an early age that medical breakthroughs hold life-changing power. At the time, Noah’s heart defect didn’t warrant immediate action, and since the treatment option was extremely invasive, he decided to take a “wait-and-see approach.” The 26-year-old’s condition ignited his passion for medical advancement and has shaped his ambitions, leading him down a path into the uniquely associated study of galaxies. Now, Noah is dedicated to uncovering the intricacies of the human immune system and how it is influenced by inflammatory environments, ultimately shedding light on this complex network of organs, cells, and proteins.

Dr. Kees-Jan Pronk wants to not only cure pediatric leukemia but also grant patients a healthy life.

Seeking answers for a healthy life after childhood leukemia

Interview with Dr. Kees-Jan Pronk, Head of Pediatric Oncology, Hematology, Immunology, and Nephrology at Skåne University Hospital in Lund (SE)

In many ways, pediatric cancers are counterintuitive. Children suffer from an insidious disease typical of old age, where developing rather than aging tissues derail and make them very sick. Treatment is harsh and debilitating as rapidly dividing cells are systemically poisoned or irradiated. And yet, kids recover. In high-income countries, over 80% of children with cancer are cured. As Head of Pediatric Oncology, Hematology, Immunology and Nephrology at Skåne University Hospital in Lund, Dr. Kees-JanPronk is at the epicenter of life-changing events for families confronting childhood cancer.

Providing patient care, managing administrative duties, and running a research lab, Kees-Jan witnesses a patient’s journey from different angles. He works with colleagues to administer therapy and manage treatment side effects. Concurrently, he documents the long-term impact of chemotherapy and explores ways to do things better. From that confluence of what is and what could be done, Kees-Jan unpacks the “counterintuitive” of childhood cancers during our interview and reveals how unique aspects of children and their malignancies have defined cancer care over time.

Dr. Marta Barisa

Fierce curiosity and the temerity to pursue it relentlessly

Interview with Dr. Marta Barisa, Senior Research Fellow at the Great Ormond Street Institute of Child Health University College London (UK)

The term ‘innovation’ gets thrown around quite a bit. Influencers splash it across the internet; consulting firms sell its promises; some 70,000 books map out how to achieve it. In that onslaught of advice and business plans, the word has lost meaning. So, it’s refreshing to hear Dr. Marta Barisa talk about her research. She and her colleagues at the UCL Great Ormond Street Institute of Child Health tackle difficult-to-treat cancers by engaging in bold exploration and creative detective work. What Marta calls experimental pediatric oncology is really a foray into the thousand unknowns of why, when, and how cell therapies work. Using every tool at their disposal, Marta and her colleagues leave no idea untried and no assumption uncontested to turn around the paucity of successful cell therapies for solid tumors. In conceding how little we understand, Marta and her colleagues see every attempt to coax immune cells into antitumor action as an opportunity to effect change. And that is true innovation.

Dr. Nazia Matto expands regulatory T cells used to treat patients.

On resetting rogue immune cells and oneself

Interview with Dr. Nazia Matto, Research Associate and Lead Production Scientist in the Department of Hematology at King’s College London (UK)

Nazia Matto sits comfortably in front of her computer. She smiles almost imperceptibly as she evaluates how best to describe her current position at King’s College London. It was meant to be a split position. Some of her time, she would harvest and expand regulatory T cells from patients with aplastic anemia as part of a Phase I dose study to treat their condition. The rest of her time, she would conduct the analysis of the samples collected from these patients before and after the treatment infusion. And yet, at this point, she finds herself working full-time on production.

“The challenge that I face is that we are harvesting these cells from anemic patients,” Nazia explains. “So, even though we are using a leukapheresis product as starting material for each patient, their overall deficiency compared to normal subjects means that we are starting expansion from very low numbers of T cells. That raises the possibility that we might not achieve the desired dose.” Nazia doesn’t mind the change in plans. The loads of paperwork she manages or the 12 to 14 hours on her feet when cells are collected from patients also don’t bother her. But she does think a lot about the responsibility of producing what is a last-resort treatment for the patients in the study.

Ana Pilar Rubio Gomez

How to spot a multipotentialite: a case for being like a stem cell

Interview with Ana Pilar Rubio Gomez, Scientist in Cell Process Development at Orchard Therapeutics (UK)

A multipotentialite is someone with many intellectual and creative pursuits. They dive into one topic, resurfacing with skills and competencies. Then they discover a next interest which they pursue with the same elan. That doesn’t mean that they are unfocused. Quite the contrary. Each intellectual or creative foray is a path of intense, fast, and even fearless learning. What they learn, they expertly merge into a grander whole, no matter how disparate the concepts may seem. And the allure of new knowledge and experiences makes them thrive on diversity of situation, companionship, and challenges. Ana Rubio is a multipotentialite. She laughs when you tell her that but then retorts, “I like to think that I’m like a stem cell. I can become whatever.” Her reply is so fitting because if there is one thing that has served as a beacon throughout her career, it has been stem cells.“I’m not passionate about just cells,” she says. “I’m passionate about stem cells. They can become anything with no more than a few signals added to a petri dish, and that’s just crazy!”

Dr. Javier del Campo

A microbiophile probes an invisible world of friends, foes, and manipulators

Interview with Dr. Javier del Campo, Group Leader at the Institute of Evolutionary Biology CSIC-UPF in Barcelona (ES) and Adjunct Professor at the Rosenstiel School of Marine, Atmospheric, and Earth Science at the University of Miami (US)

We all have a sense of what an individual is. You are distinct from your dog. But what about the microflora in your gut? Given their vital role in determining your health, might they be a part of you? And by functional extension – assuming your dog makes you smile and forces you to get out for fresh air – might your dog also be a part of you? If you’re giving this some thought, conversing with Dr. Javier del Campo would be an eye-opening experience. While the example with your dog might be a bit of a stretch, Javier explores similar questions in complex systems of organisms where the boundaries that define one individual from another are blurred. Engaged in diverse and intimate relationships, each member of these systems can drastically alter the nature, function, evolution, and survival of others. Javier is fascinated by the impact of these cross-species affairs and what they reveal about the almost-alien microscopic world.

On the Astros, astronauts, and the NK cells that live in them

Interview with Dr. Austin Bigley, Vice President and Head of Research and Development at Indapta Therapeutics (US)

“One of the things that happens in spaceflight is that people reactivate viruses, like cytomegalovirus. And it’s a weird biology, because you see the phenotypic shift associated with activated NK cells, but the cells won’t kill effectively.” Dr. Austin Bigley knows a thing or two about unexpected behavior in natural killer (NK) cells. Throughout his scientific career, he has watched NK cells respond to extreme conditions. He’s examined them in blood samples from astronauts on the International Space Station. He’s quantified outpours of NK cells into the bloodstream of subjects that are working out. And he’s documented a counterintuitive blunting of that exercise-driven effect by cytomegalovirus (CMV) infection, which normally activates NK cells. Today, Austin uses his intimate knowledge of these enigmatic cytotoxic lymphocytes at Indapta Therapeutics. As Vice President and Head of Research and Development, he is working to transform a unique population of NK cells – Fc epsilon RI gamma-deficient g-NK cells – into a powerful cancer treatment.

Of great minds and elegant science

Interview with Dr. Ahmed Ahmed, Professor of Gynecological Oncology and Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine (UK)

In ovarian cancer circles, he is recognized for his work on p53. Dr. Ahmed Ahmed’s groundbreaking paper in 2010 demonstrated that high-grade serous ovarian cancer is a p53 mutated tumor and marked the beginning of his systematic characterization of the origin and genetic drivers of the disease. His work has greatly improved the identification of ovarian cancer patients for treatment.

Unwavering. One man's quest to elevate lipids

Interview with Dr. Valerio Chiurchiù, Neuroimmunologist at the Institute of Translational Pharmacology of Rome, CNR, and Santa Lucia Foundation Hospital (IT)

Breaking new ground in the sciences takes tenacity. Courage may start you down a less traveled research path, but Valerio Chiurchiù will tell you that stubborn persistence keeps you going. Determination is your best companion in uncharted waters. Valerio is an acclaimed researcher in neuroimmunology and pathophysiology. He is also an assistant professor in the Faculty of Medicine at the University of Rome but works primarily at the Institute of Translational Pharmacology of Rome, CNR, and at the Santa Lucia Foundation Hospital. There, Valerio heads the Laboratory of Resolution of Neuroinflammation.

The value of understanding disease before it happens

Interview with Dr. Pablo Menéndez, ICREA Research Professor of Childhood Leukemia and Immunotherapy at the Josep Carreras Leukemia Research Institute (ES)

Dr. Pablo Menéndez is Campus Research Director at the Josep Carreras Leukemia Research Institute in Barcelona. He’s also an ICREA Research Professor, a title in recognition of his academic excellence. On the morning of our interview, he smiles over a hot cup of tea. He shares that later he will call his 92-year-old father and then have lunch with his kids. It’s Father’s Day in Spain.

A Swedish lab at the epicenter of converging worlds and ideas

Interview with Dr. Magnus Essand, Professor of Gene Therapy, and Dr. Di Yu, Associate Professor of Immunotherapy at Uppsala University (SE)

The story of Magnus Essand and Di Yu is compelling in many ways. There’s the fact that they have been working together for nearly 15 years. There’s their approach in arming the immune system to not only attack cancerous cells but also obviate cancer’s escape from that offensive. And of course, their involvement in a publicly traded spin-off company to overcome the financial wasteland between lab and clinic. But what is striking about the storyline is its pattern of different life paths and ideas that converge into a collage of complementarity and opportunities.

Science in Africa is science for the world. A clear message from Resty Nabeeta and Maike de la Roche.

Interview with graduate student Resty Nabeeta from Makerere University, Kampala (UG), and group leader Dr. Maike de la Roche from the Cancer Research UK Cambridge Institute (UK)

The world is becoming increasingly small. Activities in one corner of the planet influence, burden, empower, or wreak havoc in another. Human existence – in numbers, behavior, and impact – reverberates across natural and political boundaries, conquering distances with the incessant crisscrossing of container ships, flights, and Zoom calls. Oddly, how humans tackle the aftermath of globalization often remains localized, limited in reach, time, or inclusion. But if the very nature of society makes challenges global, then science must respond in kind. That impulse brought together Resty Nabeeta and Dr. Maike de la Roche on a gray morning in Edinburgh, just before heading to the buzzing poster halls and talks of the British Society of Immunology (BSI) Congress 2021.

Iben Lundgaard and the modern science lab:hip, focused, and empowered

Interview with Dr. Iben Lundgaard, Associate Professor at the Wallenberg Centre for Molecular Medicine, Lund University (SE)

“I never thought I would become a professor. When I was younger and at university, I thought of a professor as a gray-haired older male. That was my stereotype of a professor and I thought, ‘this is not for me; I will never be a professor.’ But now I am only one promotion away from becoming a professor.” Dr. Iben Lundgaard chuckles about that starting point to a career that led to an Associate Professorship at Lund University. In fact, Iben paints a stark contrast to the stereotypic image of an absentminded, out-of-touch, middle-aged academic. Iben is under 40 and female. She guides a productive research lab, insists on keeping science fun, and broadcasts their findings on social media. Add that Iben’s research focuses on a structure of the brain – the glymphatic system – that was first described just 8 years ago and you have the formula for today’s modern lab where tomorrow’s experts unfold their scientific curiosity.

Rachel Abbott on seizing opportunities and pushing your own boundaries

Interview with Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio (UK)

Rather early in life, Dr. Rachel Abbott realized that taking what others considered the safest route was not always the most interesting choice. In fact, by repeatedly deciding to take risks and learn something new, Rachel’s path has been an impressive progression through a spectrum of research areas and increased leadership. Today she is a young, successful pioneer in the biotech industry, heading up teams at Enara Bio to develop novel TCR-directed immunotherapies and discover unconventional cancer antigens.

The Sohlberg-Björklund duet: orchestrating successful therapies with natural killer cells

Interview with Dr. Ebba Sohlberg, project manager in the Center for Infectious Medicine at the Karolinska Institute and Dr. Andreas Björklund, clinician in the unit for Cell Therapy and Allogeneic Stem Cell Transplantation (CAST) of the Karolinska University Hospital, Stockholm (SE)

A new generation of NK cell therapies are under development at the Karolinska Institute and Karolinska University Hospital. Drs. Ebba Sohlberg and Andreas Björklund are part of a large team led by Professor Karl-Johan Malmberg that focuses on understanding the mechanisms underlying the diversification of human NK cell repertoires and implementing novel insights into NK cell biology in clinical trials for advanced cancer patients. Andreas was the PI for their recently closed clinical trial that successfully used natural killer (NK) cells to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Ebba headed the immunomonitoring. In collaboration with various healthcare and industry partners, the team is now developing a new and exciting therapy based on ‘adaptive’ NK cells.

Leader, problem solver, challenge seeker. Johanna Olweus is a force to be reckoned with.

Interview with Dr. Johanna Olweus, Professor and Head of the Department of Cancer Immunology at Oslo University Hospital (NO)

From the start, Dr. Johanna Olweus puts you at ease in a conversation – she laughs easily; she gives every question careful consideration. In the wider world, she runs a prolific research group, heads an internationally renowned research department at Oslo University Hospital, and is a professor with teaching responsibilities at the University of Oslo. And yet, at this moment, she is 100% engaged in the intimate space of your exchange. She makes you hang on her every word as she describes the experiences, thoughts, and insights that shaped her career.

Advancing science, giving guidance, embracing humanity. A stroll with Paul Fairchild.

Interview with Dr. Paul Fairchild, Associate Professor in Medicine at the Sir William Dunn School of Pathology, Fellow and Tutor in Medicine at Trinity College, University of Oxford (UK)

On any given morning in Oxford, you may see pensive scholars on their way to a college, private hall, or department at the University of Oxford. One of them will be Dr. Paul Fairchild. For over 20 years, Paul has walked to and from work. Deep in thought, he mulls over problems, ideas, plans, and keeps himself "intellectually engaged with what we are doing, rather than answering infinite e-mails, which is more the norm, unfortunately."

Paul Klenerman and the fine art of serendipity surfing

Interview with Dr. Paul Klenerman, Sidney Truelove Professor of Gastroenterology at the Nuffield Department of Medicine, University of Oxford (UK)

Google Paul Klenerman and you’ll stumble upon a Wikipedia page listing past accomplishments of a young fencing champion. What he does today is splashed across numerous other websites and videos with terms like University of Oxford, viral immunology, T-cell responses, HIV, hepatitis C, host-virus interactions.

A far cry from “Little Tortoise". Jonas Nilsson in four acts.

Interview with Dr. Jonas Nilsson, Inaugural Perkins Chair of Melanoma Discovery at the Harry Perkins Institute of Medical Research (AU) and Professor in Experimental Cancer Surgery at the University of Gothenburg (SE)

Conversations with some people take you on an unexpected journey of unique perspectives and tantalizing insights. That’s the case with Dr. Jonas Nilsson. Last November, he packed up the family and moved across the globe from Sweden to Western Australia on a personal and professional expedition. He isn’t trekking through the Australian bush. Instead, he is clearing a path for clinical melanoma research out of Perth. In the process, he’s seized the opportunity to leave a positive mark, regardless of where life takes him next. Taking chances runs deep in his career and has prevented stagnation on more than one occasion.

Stem cell wrangler by day, therapy maker… also by day. This is Agnete Kirkeby.

Interview with Dr. Agnete Kirkeby, Associate Professor at the University of Copenhagen (DK) and Lund University (SE)

“My mom helps making new medicines.” As simple as that sounds, Dr. Agnete Kirkeby’s ten-year-old daughter describes her mother’s work perfectly. Not only what she does, but also the reason that sustains her tenacity in a field that demands patience and precision like few others.